argenx SE (EBR:ARGX)
Belgium · Delayed Price · Currency is EUR | Market Cap | 42.93B +41.0% |
| Revenue (ttm) | 4.11B +79.4% |
| Net Income | 1.29B +39.9% |
| EPS | 19.51 +41.1% |
| Shares Out | 62.19M |
| PE Ratio | 35.39 |
| Forward PE | 27.27 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 79,819 |
| Average Volume | 79,985 |
| Open | 688.00 |
| Previous Close | 690.40 |
| Day's Range | 687.00 - 707.20 |
| 52-Week Range | 456.60 - 810.00 |
| Beta | -0.06 |
| RSI | 59.51 |
| Earnings Date | May 7, 2026 |
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave’s disease, myositis, Sjögren’s disease, system... [Read more]
Financial Performance
In 2025, argenx SE's revenue was $4.24 billion, an increase of 88.44% compared to the previous year's $2.25 billion. Earnings were $1.29 billion, an increase of 55.10%.
Financial numbers in USD Financial StatementsNews
ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1059
ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1059
Argenx price target raised to $1,059 from $1,007 at Evercore ISI
Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Argenx (ARGX) to $1,059 from $1,007 and keeps an Outperform rating on the shares.
FMR LLC's Strategic Acquisition of Argenx SE Shares
FMR LLC's Strategic Acquisition of Argenx SE Shares
argenx SE at Bank of America Global Healthcare Conference Transcript
argenx SE at Bank of America Global Healthcare Conference Transcript
argenx SE Transcript: Bank of America Global Healthcare Conference 2026
FDA leadership turnover and regulatory uncertainty are shaping the policy landscape, with drug pricing, demonstration programs, and China-related supply chain issues dominating discussions. Major healthcare legislation is unlikely before the election, and industry faces ongoing pressure to adapt to shifting regulatory and political dynamics.
argenx SE Transcript: Bank of America Global Healthcare Conference 2026
FDA leadership turnover and regulatory uncertainty dominate the policy landscape, with drug pricing reforms and MFN agreements creating long-term industry vulnerabilities. China’s rise in biopharma is accelerating, prompting bipartisan concern but limited immediate legislative action. Expect regulatory focus and oversight to increase post-election, with major reforms unlikely this year.
Argenx price target raised to $1,016 from $1,013 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Argenx (ARGX) to $1,016 from $1,013 and keeps a Buy rating on the shares. Approval of Vyvgart and Vyvgart Hytrulo…
Argenx Wins FDA Nod Expanding VYVGART Label To All Adult GMG Patients
(RTTNews) - argenx SE (ARGX) announced that the U.S. FDA has approved a label expansion for VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the trea...
argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis
argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis
Argenx (ARGX) Gains FDA Approval for Expanded Vyvgart Use
Argenx (ARGX) Gains FDA Approval for Expanded Vyvgart Use
Argenx: FDA approves label expansion for Vyvgart, Vvygart Hytrulo
Argenx (ARGX) announced the U.S. FDA approved a label expansion for Vyvgart and Vyvgart Hytrulo for the treatment of adult patients with generalized myasthenia gravis. The approved supplemental Biolog...
argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and tr...
ARGX Maintained by Guggenheim -- Price Target Raised to $1135
ARGX Maintained by Guggenheim -- Price Target Raised to $1135
ARGX Maintained by Wells Fargo -- Price Target Raised to $1260
ARGX Maintained by Wells Fargo -- Price Target Raised to $1260
Argenx price target lowered to $1,170 from $1,230 at Morgan Stanley
Morgan Stanley analyst Sean Laaman lowered the firm’s price target on Argenx (ARGX) to $1,170 from $1,230 and keeps an Overweight rating on the shares.
Argenx price target raised to $1,135 from $1,120 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Argenx (ARGX) to $1,135 from $1,120 and keeps a Buy rating on the shares. The firm adjusted estimates following the
Argenx price target raised to $1,260 from $1,247 at Wells Fargo
Wells Fargo raised the firm’s price target on Argenx (ARGX) to $1,260 from $1,247 and keeps an Overweight rating on the shares. The firm says Vyvgart’s growth remains durable with
Argenx price target lowered to $1,222 from $1,227 at Stifel
Stifel lowered the firm’s price target on Argenx (ARGX) to $1,222 from $1,227 and keeps a Buy rating on the shares following an in-line Q1 report. Despite seasonality headwinds, management
Argenx Obliterates Profit Expectations On 'Solid Print' For Its Immunology Powerhouse
Argenx stock rose early Thursday on better-than-expected first-quarter profit, though sales missed some forecasts.
argenx SE Earnings Call Transcript: Q1 2026
Q1 2026 saw 63% revenue growth and strong operating leverage, with VYVGART leading in MG and CIDP and multiple label expansions and pipeline catalysts ahead. Vision 2030 remains the strategic focus, supported by robust cash and continued investment in innovation.
argenx SE Earnings Call Transcript: Q1 2026
Q1 2026 saw 63% revenue growth to $1.3B, strong operating leverage, and expanding VYVGART adoption in MG and CIDP. Pipeline progress and label expansions are set to drive further growth, with robust cash reserves supporting continued investment.
argenx SE Earnings release: Q1 2026
argenx SE released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
argenx SE Slides: Q1 2026
argenx SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
argenx SE Earnings release: Q1 2026
argenx SE released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
argenx SE Slides: Q1 2026
argenx SE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.